Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Science

13 Apr 2022

New Study Shows Psilocybin Rewires Brain After Depression

Published by a team of top researchers including David Nutt & Robin Carhart-Harris, a new study shows that psilocybin-assisted therapy causes observable changes in brain patterns associated with depression....

By Jason Najum

Breaking News, Industry

12 Apr 2022

Breaking News: Numinus Wellness to Acquire Novamind

We’ve been expecting this to happen in one way or another....

By Jason Najum

Don’t Miss

11 Apr 2022

News You Might Have Missed: April 11th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic news items to help you catch up and stay informed....

By Jason Najum

Finance

8 Apr 2022

Christian Angermayer Buys 1 Million Shares of ATAI

Psychedelic medicine is a long-term play and atai founder Christian Angermayer has just given us a multi-million dollar reminder...

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Law & Politics

6 Apr 2022

Health Canada Approves First Special Access Request for Psilocybin

The first known case of psilocybin being delivered to patients through Canada’s Special Access Program...

By Jason Najum

Industry

5 Apr 2022

Field Trip Granted Patent for Lead Compound FT-104

Today they continued to deliver on their projected milestones with the announcement that the patent has been formally granted and gives exclusive rights to Field Trip....

By Jason Najum

Industry

5 Apr 2022

Stifel Initiates (Positive) Coverage on Awakn Life Sciences

Investment firm Stifel GMP has initiated coverage on Awakn and their prognostication is pretty positive....

By Jason Najum

Don’t Miss

4 Apr 2022

News You Might Have Missed: April 4th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic news items to help you catch up and stay informed....

By Jason Najum

Finance

30 Mar 2022

ATAI Announces Fourth Quarter and Full Year 2021 Results

With the sector in the midst of a (very) extended pullback, these results provide opportunities to re-focus our attention on the details of the company’s progress and away from the...

By Jason Najum

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.